Funds holding Pyxis Oncology Inc
ISIN US7473241013 · United States
- Fund holders
- 19
- Of which ETFs
- 3 16 other funds
- Value held
- ≈ 10.5M $ 8.9M $ · 15.3M SEK
- Share of capital
- 5.1 % of 83.4M shares on Aug 12, 2026
| Fund | Shares | Value | Weight in fund | Share of capital | |
|---|---|---|---|---|---|
| VANGUARD TOTAL STOCK MARKET INDEX FUND VANGUARD INDEX FUNDS | 1,422,296 | 4.3M $ | 0.00 % | 1.71 % | as of Jun 30, 2026 ↗ |
| HealthInvest Sustainable Healthcare Atle Fund Management AB | 771,994 | 10.7M SEK | 0.33 % | 0.93 % | as of Mar 31, 2026 ↗ |
| VANGUARD EXTENDED MARKET INDEX FUND VANGUARD INDEX FUNDS | 558,775 | 1.7M $ | 0.00 % | 0.67 % | as of Jun 30, 2026 ↗ |
| iShares Biotechnology ETF iShares Trust | 374,680 | 1.1M $ | 0.01 % | 0.45 % | as of Jun 30, 2026 ↗ |
| HealthInvest Small & Mid Cap Healthcare Atle Fund Management AB | 336,262 | 4.6M SEK | 0.47 % | 0.40 % | as of Mar 31, 2026 ↗ |
| Fidelity Extended Market Index Fund Fidelity Concord Street Trust | 271,545 | 488.8K $ | 0.00 % | 0.33 % | as of May 31, 2026 ↗ |
| iShares Micro-Cap ETF iShares Trust | 166,564 | 501.4K $ | 0.03 % | 0.20 % | as of Jun 30, 2026 ↗ |
| Fidelity Total Market Index Fund Fidelity Concord Street Trust | 90,276 | 162.5K $ | 0.00 % | 0.11 % | as of May 31, 2026 ↗ |
| Fidelity Series Total Market Index Fund Fidelity Concord Street Trust | 78,709 | 141.7K $ | 0.00 % | 0.09 % | as of May 31, 2026 ↗ |
| Ultra-Small Company Market Fund Bridgeway Funds, Inc. | 70,060 | 210.9K $ | 0.14 % | 0.08 % | as of Jun 30, 2026 ↗ |
| Fidelity Nasdaq Composite Index Fund Fidelity Concord Street Trust | 38,072 | 68.5K $ | 0.00 % | 0.05 % | as of May 31, 2026 ↗ |
| VANGUARD BALANCED INDEX FUND VANGUARD VALLEY FORGE FUNDS | 26,866 | 80.9K $ | 0.00 % | 0.03 % | as of Jun 30, 2026 ↗ |
| VANGUARD INSTITUTIONAL TOTAL STOCK MARKET INDEX FUND VANGUARD INSTITUTIONAL INDEX FUNDS | 26,650 | 80.2K $ | 0.00 % | 0.03 % | as of Jun 30, 2026 ↗ |
| 1290 VT Micro Cap Portfolio EQ Advisors Trust | 11,188 | 33.7K $ | 0.02 % | 0.01 % | as of Jun 30, 2026 ↗ |
| U.S. MICRO CAP PORTFOLIO DFA INVESTMENT DIMENSIONS GROUP INC | 10,263 | 27.2K $ | 0.00 % | 0.01 % | as of Jul 31, 2026 ↗ |
| Victory Extended Market Index Fund Victory Portfolios III | 5,968 | 15.8K $ | 0.00 % | 0.01 % | as of Jul 31, 2026 ↗ |
| JNL/DFA U.S. Small Cap Fund JNL Series Trust | 3,922 | 11.8K $ | 0.00 % | 0.00 % | as of Jun 30, 2026 ↗ |
| Invesco Nasdaq Biotechnology ETF Invesco Exchange-Traded Fund Trust II | 3,278 | 5.9K $ | 0.01 % | 0.00 % | as of May 31, 2026 ↗ |
| ProShares Ultra Nasdaq Biotechnology ProShares Trust | 2,303 | 4.1K $ | 0.01 % | 0.00 % | as of May 31, 2026 ↗ |
The funds most exposed to it
The weight is the share of a fund's net assets. The holders table ranks funds by number of shares. This one ranks them by the weight of the company in each fund.
| Fund | Weight in fund | |
|---|---|---|
| HealthInvest Small & Mid Cap Healthcare Atle Fund Management AB | 0.47 % | as of Mar 31, 2026 ↗ |
| HealthInvest Sustainable Healthcare Atle Fund Management AB | 0.33 % | as of Mar 31, 2026 ↗ |
| Ultra-Small Company Market Fund Bridgeway Funds, Inc. | 0.14 % | as of Jun 30, 2026 ↗ |
| iShares Micro-Cap ETF iShares Trust | 0.03 % | as of Jun 30, 2026 ↗ |
| 1290 VT Micro Cap Portfolio EQ Advisors Trust | 0.02 % | as of Jun 30, 2026 ↗ |
| iShares Biotechnology ETF iShares Trust | 0.01 % | as of Jun 30, 2026 ↗ |
| Invesco Nasdaq Biotechnology ETF Invesco Exchange-Traded Fund Trust II | 0.01 % | as of May 31, 2026 ↗ |
| ProShares Ultra Nasdaq Biotechnology ProShares Trust | 0.01 % | as of May 31, 2026 ↗ |
| Victory Extended Market Index Fund Victory Portfolios III | 0.00 % | as of Jul 31, 2026 ↗ |
| VANGUARD EXTENDED MARKET INDEX FUND VANGUARD INDEX FUNDS | 0.00 % | as of Jun 30, 2026 ↗ |
Quarter after quarter
Each row is one quarter of SEC filings, newest first. The change compares each quarter with the one before.
| Quarter | Holders | Change | Shares | Change |
|---|---|---|---|---|
| 2026Q3 | 17 | 0 | 3,161,415 | +3.7 % |
| 2026Q2 | 17 | -5 | 3,049,950 | -5.1 % |
| 2026Q1 | 22 | +4 | 3,214,874 | +16.7 % |
| 2025Q4 | 18 | -19 | 2,754,316 | -23.7 % |
| 2025Q3 | 37 | -37 | 3,610,787 | -45.2 % |
| 2025Q2 | 74 | -4 | 6,584,419 | -2.8 % |
| 2025Q1 | 78 | -6 | 6,773,320 | +5.0 % |
| 2024Q4 | 84 | +43 | 6,448,982 | +92.7 % |
| 2024Q3 | 41 | +18 | 3,347,461 | +56.9 % |
| 2024Q2 | 23 | +2 | 2,133,177 | +5.1 % |
| 2024Q1 | 21 | -3 | 2,029,729 | +7.1 % |
| 2023Q4 | 24 | 1,895,370 |
Institutional managers
74 managers declare this company to the SEC (Form 13F). The table shows the 25 largest.
| Manager | Shares | Value | |
|---|---|---|---|
| Pfizer Inc | 7,032,770 | 9.2M $ | as of Mar 31, 2026 |
| Laurion Capital Management LP | 4,997,333 | 7.3M $ | as of Mar 31, 2026 |
| GordonMD Global Investments LP | 4,121,870 | 6M $ | as of Mar 31, 2026 |
| Palo Alto Investors LP | 1,010,510 | 1.5M $ | as of Mar 31, 2026 |
| 683 Capital Management, LLC | 896,263 | 1.3M $ | as of Mar 31, 2026 |
| RENAISSANCE TECHNOLOGIES LLC | 888,680 | 1.3M $ | as of Mar 31, 2026 |
| BlackRock, Inc. | 788,839 | 1.2M $ | as of Mar 31, 2026 |
| GEODE CAPITAL MANAGEMENT, LLC | 598,121 | 873.8K $ | as of Mar 31, 2026 |
| Longaeva Partners L.P. | 503,214 | 734.7K $ | as of Mar 31, 2026 |
| JACOBS LEVY EQUITY MANAGEMENT, INC | 460,997 | 673.1K $ | as of Mar 31, 2026 |
| MILLENNIUM MANAGEMENT LLC | 397,625 | 580.5K $ | as of Mar 31, 2026 |
| MARSHALL WACE, LLP | 354,417 | 517.4K $ | as of Mar 31, 2026 |
| Decheng Capital LLC | 326,810 | 477.1K $ | as of Mar 31, 2026 |
| JANE STREET GROUP, LLC | 304,459 | 444.5K $ | as of Mar 31, 2026 |
| UBS Group AG | 254,124 | 371K $ | as of Mar 31, 2026 |
| STATE STREET CORP | 248,837 | 363.3K $ | as of Mar 31, 2026 |
| XTX Topco Ltd | 200,096 | 292.1K $ | as of Mar 31, 2026 |
| Atle Fund Management AB | 197,036 | 1.6M $ | as of Mar 31, 2026 |
| ACADIAN ASSET MANAGEMENT LLC | 144,256 | 209 $ | as of Mar 31, 2026 |
| Bank of New York Mellon Corp | 133,996 | 195.6K $ | as of Mar 31, 2026 |
| NewEdge Wealth, LLC | 116,006 | 169.4K $ | as of Mar 31, 2026 |
| NORTHERN TRUST CORP | 101,948 | 148.8K $ | as of Mar 31, 2026 |
| BRIDGEWAY CAPITAL MANAGEMENT, LLC | 81,260 | 118.6K $ | as of Mar 31, 2026 |
| TWO SIGMA INVESTMENTS, LP | 73,300 | 107K $ | as of Mar 31, 2026 |
| MORGAN STANLEY | 69,688 | 101.7K $ | as of Mar 31, 2026 |
Declared shareholders of Pyxis Oncology Inc
There are 2 beneficial ownership filings. These stakes do not add up. An asset manager that files includes its own funds, which already appear among the funds on this page.
| Shareholder | Declared stake | Shares | |
|---|---|---|---|
| GordonMD Global Investments LP and 3 others | 12.10 % | 10,024,909 | as of Jun 30, 2026 · SCHEDULE 13G |
| BIOTECHNOLOGY VALUE FUND L P and 9 others | 9.99 % | 8,336,902 | as of Jul 2, 2026 · SCHEDULE 13G |
Cite this page
Titelia. "Funds holding Pyxis Oncology Inc". https://titelia.com/en/stocks/pyxis-oncology-inc-US7473241013